A systematic review found that patients who were switched from one biosimilar to another did not experience a change in clinical outcomes or an increase in adverse events.
In light of the growing evidence that supports the safety of switching from a reference product to a biosimilar, a systematic review reveals that biosimilar-to-biosimilar switching may also be safe for patients.
The review, which was published in BioDrugs, compiled data from 23 observational studies, selected from 982 original findings, to answer the question of whether switching patients from a biosimilar to another contributed to adverse clinical outcomes, including reduced efficacy or compromised safety.
Patients may have to switch from a reference biologic to a biosimilar or from one biosimilar to another because of changing insurance mandates, pharmacy benefit managers interfering in formulary placements, or policy limitations intended to reduce costs. Additionally, patients may be subject to different drug coverage while they’re traveling or if they relocate to another region.
A US survey found that 70% of patients with cancer don’t know what biosimilars are. The authors noted that some patients and providers may assume that because a biosimilar is cheaper and was approved using a different clinical development paradigm compared to a reference product that a biosimilar may lead to increases in adverse events or reduced effectiveness. Another issue is that patients who are told to switch to a biosimilar may experience the nocebo effect, where a patient’s negative attitude towards a product results in adverse clinical outcomes.
“The possibility of multiple switches between biosimilars of the same reference biologic is already a reality, and these types of switches are expected to become more common in the future…. Proof that biosimilars from the same reference biologic are equivalent in terms of effectiveness and safety is required to support switching between biosimilars of the same reference biologic,” the authors wrote.
The authors conducted an electronic database search for US- or EU-based studies that involved biosimilar-to-biosimilar switching through the end of December 2021. The studies could assess biosimilars for erythropoietin, human growth hormone, filgrastim, etanercept, adalimumab, infliximab, and rituximab. The literature had to be human studies published in English.
Among the 23 real-world observational studies that were included in their analysis, 13 were published in peer-reviewed journals and 10 derived from abstracts shared at conferences. The studies were heterogenous in size, design, and endpoints. Overall, 3657 patients were involved, and no randomized control trials were identified.
The majority of the studies focused on switches between infliximab biosimilars (n = 17), followed by adalimumab biosimilars (n = 3), etanercept biosimilar (n = 2), and rituximab biosimilars (n = 1).
The authors concluded that although the number of available studies was small, their review demonstrated that biosimilar-to-biosimilar switching did not compromise patients’ safety or clinical outcomes. They also stressed that physicians, nurses, and clinical pharmacists could play a critical role in educating patients on the safety, efficacy, and benefits of biosimilars as well as influencing biosimilar adoption.
The authors mentioned several limitations of the review, including the observational nature of the studies and the inclusion of potentially non-peer-reviewed abstracts that may only contain preliminary or interim data. It was noted that as more switches occur in the future, more data on biosimilar-to-biosimilar switched will emerge.
“Given that it is a current topic of interest to HCPs, their patients, and healthcare systems, it is useful to collate and evaluate existing data even while acknowledging that additional data will likely become available in the future,” they wrote.
Reference
Cohen HP, Hachaichi S, Bodenmueller W, Kvien TK, Danese S, Blauvelt A. Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies. BioDrugs. Published online July 6, 2022. doi:10.1007/s40259-022-00546-6
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.